TY - JOUR
T1 - Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols
T2 - the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects
AU - Gryaznov, Dmitry
AU - Odutayo, Ayodele
AU - von Niederhäusern, Belinda
AU - Speich, Benjamin
AU - Kasenda, Benjamin
AU - Ojeda-Ruiz, Elena
AU - Blümle, Anette
AU - Schandelmaier, Stefan
AU - Mertz, Dominik
AU - Tomonaga, Yuki
AU - Amstutz, Alain
AU - Pauli-Magnus, Christiane
AU - Gloy, Viktoria
AU - Bischoff, Karin
AU - Wollmann, Katharina
AU - Rehner, Laura
AU - Lohner, Szimonetta
AU - Meerpohl, Joerg J
AU - Nordmann, Alain
AU - Klatte, Katharina
AU - Ghosh, Nilabh
AU - Heravi, Ala Taji
AU - Wong, Jacqueline
AU - Chow, Ngai
AU - Hong, Patrick Jiho
AU - Cord, Kimberly Mc
AU - Sricharoenchai, Sirintip
AU - Busse, Jason W
AU - Agarwal, Arnav
AU - Saccilotto, Ramon
AU - Schwenkglenks, Matthias
AU - Moffa, Giusi
AU - Hemkens, Lars G
AU - Hopewell, Sally
AU - von Elm, Erik
AU - Briel, Matthias
PY - 2020/10/28
Y1 - 2020/10/28
N2 - BACKGROUND: Clearly structured and comprehensive protocols are an essential component to ensure safety of participants, data validity, successful conduct, and credibility of results of randomized clinical trials (RCTs). Funding agencies, research ethics committees (RECs), regulatory agencies, medical journals, systematic reviewers, and other stakeholders rely on protocols to appraise the conduct and reporting of RCTs. In response to evidence of poor protocol quality, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guideline was published in 2013 to improve the accuracy and completeness of clinical trial protocols. The impact of these recommendations on protocol completeness and associations between protocol completeness and successful RCT conduct and publication remain uncertain.OBJECTIVES AND METHODS: Aims of the Adherence to SPIrit REcommendations (ASPIRE) study are to investigate adherence to SPIRIT checklist items of RCT protocols approved by RECs in the UK, Switzerland, Germany, and Canada before (2012) and after (2016) the publication of the SPIRIT guidelines; determine protocol features associated with non-adherence to SPIRIT checklist items; and assess potential differences in adherence across countries. We assembled an international cohort of RCTs based on 450 protocols approved in 2012 and 402 protocols approved in 2016 by RECs in Switzerland, the UK, Germany, and Canada. We will extract data on RCT characteristics and adherence to SPIRIT for all included protocols. We will use multivariable regression models to investigate temporal changes in SPIRIT adherence, differences across countries, and associations between SPIRIT adherence of protocols with RCT registration, completion, and publication of results. We plan substudies to examine the registration, premature discontinuation, and non-publication of RCTs; the use of patient-reported outcomes in RCT protocols; SPIRIT adherence of RCT protocols with non-regulated interventions; the planning of RCT subgroup analyses; and the use of routinely collected data for RCTs.DISCUSSION: The ASPIRE study and associated substudies will provide important information on the impact of measures to improve the reporting of RCT protocols and on multiple aspects of RCT design, trial registration, premature discontinuation, and non-publication of RCTs observing potential changes over time.
AB - BACKGROUND: Clearly structured and comprehensive protocols are an essential component to ensure safety of participants, data validity, successful conduct, and credibility of results of randomized clinical trials (RCTs). Funding agencies, research ethics committees (RECs), regulatory agencies, medical journals, systematic reviewers, and other stakeholders rely on protocols to appraise the conduct and reporting of RCTs. In response to evidence of poor protocol quality, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guideline was published in 2013 to improve the accuracy and completeness of clinical trial protocols. The impact of these recommendations on protocol completeness and associations between protocol completeness and successful RCT conduct and publication remain uncertain.OBJECTIVES AND METHODS: Aims of the Adherence to SPIrit REcommendations (ASPIRE) study are to investigate adherence to SPIRIT checklist items of RCT protocols approved by RECs in the UK, Switzerland, Germany, and Canada before (2012) and after (2016) the publication of the SPIRIT guidelines; determine protocol features associated with non-adherence to SPIRIT checklist items; and assess potential differences in adherence across countries. We assembled an international cohort of RCTs based on 450 protocols approved in 2012 and 402 protocols approved in 2016 by RECs in Switzerland, the UK, Germany, and Canada. We will extract data on RCT characteristics and adherence to SPIRIT for all included protocols. We will use multivariable regression models to investigate temporal changes in SPIRIT adherence, differences across countries, and associations between SPIRIT adherence of protocols with RCT registration, completion, and publication of results. We plan substudies to examine the registration, premature discontinuation, and non-publication of RCTs; the use of patient-reported outcomes in RCT protocols; SPIRIT adherence of RCT protocols with non-regulated interventions; the planning of RCT subgroup analyses; and the use of routinely collected data for RCTs.DISCUSSION: The ASPIRE study and associated substudies will provide important information on the impact of measures to improve the reporting of RCT protocols and on multiple aspects of RCT design, trial registration, premature discontinuation, and non-publication of RCTs observing potential changes over time.
KW - Canada
KW - Clinical Trial Protocols as Topic
KW - Cross-Sectional Studies
KW - Ethics Committees, Research
KW - Germany
KW - Humans
KW - Switzerland
U2 - 10.1186/s13063-020-04808-y
DO - 10.1186/s13063-020-04808-y
M3 - Article (Academic Journal)
C2 - 33115541
SN - 1745-6215
VL - 21
SP - 896
JO - Trials
JF - Trials
IS - 1
ER -